Joy Cavagnaro

2.3k total citations
46 papers, 1.4k citations indexed

About

Joy Cavagnaro is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Joy Cavagnaro has authored 46 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 15 papers in Immunology and 11 papers in Oncology. Recurrent topics in Joy Cavagnaro's work include Monoclonal and Polyclonal Antibodies Research (9 papers), CAR-T cell therapy research (9 papers) and Biosimilars and Bioanalytical Methods (9 papers). Joy Cavagnaro is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), CAR-T cell therapy research (9 papers) and Biosimilars and Bioanalytical Methods (9 papers). Joy Cavagnaro collaborates with scholars based in United States, Switzerland and United Kingdom. Joy Cavagnaro's co-authors include Elmer J. Rauckman, Gerald M. Rosen, Anthony D. Dayan, Raymond P. Goodrich, Shayne C. Gad, Heather L. Reddy, Junzhi Li, Beatriz Silva Lima, Pauline L. Martin and Meredith S. Rocca and has published in prestigious journals such as The Journal of Cell Biology, Nature reviews. Immunology and Nature Biotechnology.

In The Last Decade

Joy Cavagnaro

46 papers receiving 1.4k citations

Peers

Joy Cavagnaro

IMMUN

RNMI

ONCOL

GENET

Bruce Jaffee United States

Takeshi Hara Japan

Bo Åkerström Sweden

Abbie Celniker United States

David G. Williams United Kingdom

Tamio Koizumi Japan

Maria Allhorn Sweden

Susumu Kishimoto Japan

Tao Huang China

Paula Belloni United States

Bruce Jaffee United States

Joy Cavagnaro

775 ×1.4

536 ×1.7

IMMUN

101 ×0.5

RNMI

261 ×1.3

ONCOL

361 ×2.2

GENET

Citations per year, relative to Joy Cavagnaro Joy Cavagnaro (= 1×) peers Bruce Jaffee

Countries citing papers authored by Joy Cavagnaro

Since Specialization

Citations

This map shows the geographic impact of Joy Cavagnaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Cavagnaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Cavagnaro more than expected).

Fields of papers citing papers by Joy Cavagnaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Cavagnaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Cavagnaro. The network helps show where Joy Cavagnaro may publish in the future.

Co-authorship network of co-authors of Joy Cavagnaro

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Cavagnaro. A scholar is included among the top collaborators of Joy Cavagnaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Cavagnaro. Joy Cavagnaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luetjens, C. Marc, Antje Fuchs, Peter J. Hall, et al.. (2025). Subcutaneous zilucoplan: Evaluation of reproductive toxicology. Reproductive Toxicology. 134. 108877–108877. 1 indexed citations

Cauvin, Annick, Kevin Brady, Joy Cavagnaro, & C. Marc Luetjens. (2024). Evaluation of the effect of rozanolixizumab on pregnancy outcomes and pre- and postnatal development in cynomolgus monkeys. Reproductive Toxicology. 132. 108823–108823. 2 indexed citations

MacLachlan, Timothy K., Joy Cavagnaro, Laura Andrews, et al.. (2021). Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019. Regulatory Toxicology and Pharmacology. 121. 104872–104872. 5 indexed citations

Hutt, Julie A., Basel T. Assaf, Brad Bolon, et al.. (2021). Scientific and Regulatory Policy Committee Points to Consider: Nonclinical Research and Development of In Vivo Gene Therapy Products, Emphasizing Adeno-Associated Virus Vectors. Toxicologic Pathology. 50(1). 118–146. 16 indexed citations

Rocca, Meredith S., LaRonda L. Morford, Diann Blanset, et al.. (2018). Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals. Regulatory Toxicology and Pharmacology. 98. 69–79. 13 indexed citations

Cavagnaro, Joy & Beatriz Silva Lima. (2015). Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products. European Journal of Pharmacology. 759. 51–62. 23 indexed citations

Andrews, Peter W., Joy Cavagnaro, Robert Deans, et al.. (2014). Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nature Biotechnology. 32(8). 724–726. 44 indexed citations

MacLachlan, Timothy K., et al.. (2013). Not Reinventing the Wheel: Applying the 3Rs Concepts to Viral Vector Gene Therapy Biodistribution Studies. PubMed. 24(1). 1–4. 4 indexed citations

Kornbrust, Doug, Joy Cavagnaro, Arthur A. Levin, et al.. (2013). Oligo Safety Working Group Exaggerated Pharmacology Subcommittee Consensus Document. Nucleic Acid Therapeutics. 23(1). 21–28. 32 indexed citations

10.

Alton, Eric W.F.W., Homer A. Boushey, Holger Garn, et al.. (2012). Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations. Nucleic Acid Therapeutics. 22(4). 246–254. 16 indexed citations

11.

Tibbitts, Jay, et al.. (2010). Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Regulatory Toxicology and Pharmacology. 58(2). 243–251. 25 indexed citations

12.

Leach, Michael W., Wendy Halpern, Carol W. Johnson, et al.. (2010). Use of Tissue Cross-reactivity Studies in the Development of Antibody-based Biopharmaceuticals. Toxicologic Pathology. 38(7). 1138–1166. 40 indexed citations

13.

Reddy, Heather L., Anthony D. Dayan, Joy Cavagnaro, et al.. (2008). Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation. Transfusion Medicine Reviews. 22(2). 133–153. 110 indexed citations

14.

Kohn, Donald B., Michel Sadelain, Cynthia E. Dunbar, et al.. (2003). American society of gene therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy. 8(2). 180–187. 120 indexed citations

15.

Cavagnaro, Joy. (2002). Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nature Reviews Drug Discovery. 1(6). 469–475. 202 indexed citations

16.

Gaylor, David W., Ronald P. Brown, Joy Cavagnaro, et al.. (1997). Health Risk Assessment Practices in the U.S. Food and Drug Administration. Regulatory Toxicology and Pharmacology. 26(3). 307–321. 12 indexed citations

17.

Henck, Judith, Joy Cavagnaro, Andrew G. Hendrickx, et al.. (1996). Reproductive toxicity testing of therapeutic biotechnology agents. Teratology. 53(3). 185–195. 23 indexed citations

18.

Mordenti, Joyce, Joy Cavagnaro, & James D. Green. (1996). Design of biological equivalence programs for therapeutic biotechnology products in clinical development: a perspective.. Pharmaceutical Research. 13(10). 1427–1437. 6 indexed citations

19.

Cavagnaro, Joy, et al.. (1992). Progress and challenges in the preclinical assessment of cytokines. Toxicology Letters. 64-65. 291–297. 6 indexed citations

20.

Cavagnaro, Joy. (1987). Immunotoxicology and the new biotechnology. Immunology Today. 8(4). 102–104. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact